Literature DB >> 1722158

Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed.

P Boyle1, R McGinn, P Maisonneuve, C La Vecchia.   

Abstract

Despite being such a common condition, morphologically prevalent in 88% of autopsies of old (greater than 80 years) men, little epidemiologic research has been undertaken on benign prostatic hyperplasia (BPH). The prevalence of BPH, and probably the incidence, increases with age although the belief that BPH is a direct consequence of aging per se still awaits proof. Many observers have concluded that the age association reflects age-related hormonal changes, although this also requires proof. BPH is a very common condition in aging men: 3 in every 10 may ultimately require surgery for this condition if current estimates of prevalence are correct. Despite its common occurrence, little is known with any degree of certainty about risk factors for BPH apart from being male, being old, and having had a pair of functioning testicles since puberty. There are good reasons why the epidemiology of BPH has remained poorly understood although the application of more epidemiologic thought could pay great dividends, particularly if prostate screening programs could be exploited maximally.

Entities:  

Mesh:

Year:  1991        PMID: 1722158     DOI: 10.1159/000471738

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  4 in total

Review 1.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 2.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; D McTavish
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 3.  Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis.

Authors:  Chengquan Ma; Jianzhong Zhang; Zhonglin Cai; Jian Xiong; Hongjun Li
Journal:  Biomed Res Int       Date:  2020-03-26       Impact factor: 3.411

4.  Efficacy and tolerability of combination therapy with alpha-blockers and phosphodiesterase-5 inhibitors compared with monotherapy for lower urinary tract symptoms: Protocol for a systematic review and network meta-analysis.

Authors:  Liu Qiangzhao; Zhang Xiaofeng; Zhou Fenghai; Lian Qiong; Zhang Fa; Guo Bohong; Xi Xinsheng
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.